(S)-2-[(R)-3-amino-4-(2-fluorophenyl)butyryl]-1,2,3,4-tetrahydroisoquinoline-3-carboxamide

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 肽模拟物
• 英文名称: (S)-2-[(R)-3-amino-4-(2-fluorophenyl)butyryl]-1,2,3,4-tetrahydroisoquinoline-3-carboxamide
• 英文别名: (3S)-2-[(3R)-3-amino-4-(2-fluorophenyl)butanoyl]-3,4-dihydro-1H-isoquinoline-3-carboxamide
• 化学式: C₂₀H₂₂FN₃O₂
• 分子量: 355.4
• InChiKey: OEVYDSSAPNIURZ-AEFFLSMTSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  26
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  89.4
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• Dpp-IV Inhibitors
  申请人：Edwards John Paul

  公开号：US20070265301A1

  公开（公告）日：2007-11-15

  The invention relates to compounds of formula (I), wherein Z, R 1-8 , n, A 1 , X 1 and X 2 have the meaning as cited in the description and the claims. Said compounds are useful as DPP-IV inhibitors. The invention also relates to the preparation of such compounds as well as the production and use thereof as medicament.

  该发明涉及式（I）的化合物，其中Z、R1-8、n、A1、X1和X2的含义如描述和权利要求所述。所述化合物可用作DPP-IV抑制剂。该发明还涉及制备这种化合物以及作为药物的生产和使用。
• DPP-IV inhibitors
  申请人：Santhera Pharmaceuticals (Deutschland) Aktiengesellschaft

  公开号：EP1598341A1

  公开（公告）日：2005-11-23

  The invention relates to compounds of formula (I) wherein Z, R1-8, n, A1, X1 and X2 have the meaning as cited in the description and the claims. Said compounds are useful as DPP-IV inhibitors. The invention also relates to the preparation of such compounds as well as the production and use thereof as medicament.

  本发明涉及式 (I) 的化合物 其中 Z、R1-8、n、A1、X1 和 X2 具有在说明书和权利要求书中引用的含义。所述化合物可用作 DPP-IV 抑制剂。本发明还涉及此类化合物的制备及其作为药物的生产和使用。
• REGULATED BIOCIRCUIT SYSTEMS
  申请人：Obsidian Therapeutics, Inc.

  公开号：US20190192691A1

  公开（公告）日：2019-06-27

  The present invention provides regulatable biocircuit systems. Such systems provide modular and tunable protein expression systems in support of the discovery and development of therapeutic modalities.
• IDENTIFICATION AND TARGETED MODULATION OF GENE SIGNALING NETWORKS
  申请人：CAMP4 THERAPEUTICS CORPORATION

  公开号：US20210254056A1

  公开（公告）日：2021-08-19

  The present invention provides methods and compositions for the evaluation, alteration and/or optimization of gene signaling. Methods and systems are also provided which exploit the information generated in the identification of new targets and non-canonical signaling pathways.
• [EN] DPP-IV INHIBITORS<br/>[FR] INHIBITEURS DPP-IV
  申请人：GRAFFINITY PHARMACEUTICALS AG

  公开号：WO2005056013A1

  公开（公告）日：2005-06-23

  The invention relates to compounds of formula (I)wherein a dotted line indicates an optionally present double bond and wherein Z, R1 - R8, n, X1, X2, Y and T have the meaning as cited in the description and the claims. Said compounds are useful as DPP-IV inhibitors. The invention also relates to the preparation of such compounds as well as the production and use thereof as medicament.